Kala Bio's gross profit for the
three
months ended in Mar. 2024 was $0.00 Mil. Kala Bio's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Kala Bio's gross profit for the
three
months ended in Mar. 2024 was $0.00 Mil. Kala Bio's Revenue for the
three
months ended in Mar. 2024 was $0.00 Mil. Therefore, Kala Bio's Gross Margin % for the quarter that ended in Mar. 2024 was N/A%.
Kala Bio had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage
During the past 9 years, the highestGross Margin % of Kala Bio was 66.94%. The lowest was 34.22%. And the median was 56.84%.
Kala Bio Gross Profit Historical Data
The historical data trend for Kala Bio's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kala Bio's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kala Bio's Gross Profit Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kala Bio's Gross Profit distribution charts can be found below:
* The bar in red indicates where Kala Bio's Gross Profit falls into.
Kala Bio Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Kala Bio's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
(Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Kala Bio (NAS:KALA) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Kala Bio had a gross margin of N/A% for the quarter that ended in Mar. 2024 => No sustainable competitive advantage
Kala Bio Gross Profit Related Terms
Thank you for viewing the detailed overview of Kala Bio's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing innovative therapies for rare and severe eye diseases. KALA's lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KALA has been successfully added to your 